Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Launched by OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIVERSITY · Mar 10, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for women with locally advanced cervical cancer. The researchers are studying the combination of two experimental drugs, Iparomlimab and Tuvonralimab, with traditional chemotherapy medicines, paclitaxel and cisplatin. This combination aims to shrink tumors before surgery, potentially improving treatment outcomes and offering hope to younger women who wish to preserve their fertility. By evaluating how well this new treatment works and its safety, the trial seeks to find better options for patients facing this challenging condition.

To be eligible for the trial, participants should be women aged 18 to 75 with specific types and stages of cervical cancer. They must not have received prior immunotherapy and should be planning to undergo surgery for their cancer. Participants can expect to have regular check-ups and monitoring during the study, and they will need to agree to use contraception if they are of childbearing age. It's an important opportunity for those looking for new treatment options and to help advance research in cervical cancer care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma.
• • 2. -Arm 1 (Locally Advanced cervical cancer): Patients with locally advanced cervical cancer classified as FIGO 2018 stages IB3, IIA2, IIB, or IIICr (lesion ≥4 cm, confirmed by MRI).
• • Arm2 (cervical cancer patients desiring fertility-sparing treatment): Patients with cervical cancer classified as FIGO 2018 stages IB2, IB3 (lesion ≤6 cm), IIA1, or IIA2 (lesion ≤6 cm) who have a strong desire to preserve fertility.
• • 3）Planned to undergo surgical treatments of cervical cancer.
• • 4) -Arm 1 (Locally Advanced cervical cancer): Age 18-75 years.
• • Arm2 (cervical cancer patients desiring fertility-sparing treatment): Age 18-45 years.
• • 5) ECOG performance status score: 0-1. 6) No prior immunotherapy received by the participant. 7) Expected survival period ≥6 months. 8) Women of childbearing potential must agree to use contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the study and for 6 months after the study ends. A negative serum or urine pregnancy test within 7 days before study enrollment is required, and the patient must not be breastfeeding.
• • 9) Adequate organ function as defined by the protocol, with test samples collected within 7 days before the start of study treatment.
• • 10) Participants voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up.
• Exclusion Criteria:
• • 1. Histological subtypes or disease stages other than those permitted in inclusion criteria 1) and 2).
• • 2. Severe hypersensitivity (≥ Grade 3) to cisplatin, paclitaxel, iparomlimab and tuvonralimab, and/or any of their excipients.
• • 3. Participation in another clinical trial within 4 weeks prior to enrollment.
• • 4. Administration of inactivated vaccines within 30 days before the first study treatment or planned vaccination during the study period.
• • 5. Treatment with systemic immunostimulants, colony-stimulating factors, interferons, interleukins, or combination vaccines within 6 weeks or 5 half-lives (whichever is shorter) before the first dose.
• • 6. Diagnosis of immunodeficiency or chronic systemic steroid therapy (exceeding 10 mg prednisone equivalent per day) or any other form of immunosuppressive therapy within 7 days before the first dose.
• • 7. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressive drugs) within the past 2 years.
• • 8. History of (non-infectious) pneumonitis requiring steroid treatment or current (non-infectious) pneumonitis.
• • 9. Active infection requiring systemic treatment.
• • 10. Known history of HIV infection.
• • 11. Known history of hepatitis B (defined as HBsAg reactivity) or active hepatitis C virus infection (defined as detectable HCV RNA \[qualitative\]).
• • 12. Known history of active tuberculosis (TB; Mycobacterium tuberculosis).
• • 13. Prior allogeneic tissue/solid organ transplantation.
• • 14. Central nervous system metastases, such as brain metastases.
• • 15. Uncontrolled pleural or peritoneal effusion.
• • 16. Impaired mobility due to pathological fractures caused by bone metastases.
• • 17. Insufficient bone marrow function (without transfusion within 14 days): a) Absolute neutrophil count (ANC) \<1.5×10⁹/L;b) Platelets \<100×10⁹/L; c) Hemoglobin \<9 g/dL.
• • 18. Liver abnormalities: a) ALT, AST, or ALP \>2.5× upper limit of normal (ULN) without liver metastasis or \>5×ULN with liver metastasis; b) Total bilirubin \>1.5×ULN (\>3×ULN in patients with Gilbert's syndrome); c) Decompensated cirrhosis (Child-Pugh class B or C); d) HBsAg-positive with HBV DNA ≥2000 IU/mL (patients with HBsAg-positive and HBV DNA \<2000 IU/mL must receive at least 2 weeks of anti-HBV therapy before the first dose); e) HCV antibody-positive with detectable HCV RNA.
• • 19. Kidney abnormalities: a) Serum creatinine \>1.5×ULN or estimated creatinine clearance \<60 mL/min using the Cockcroft-Gault formula; b) Urinalysis showing protein ≥++ and confirmed 24-hour urine protein \>1.0 g; c) Renal failure requiring hemodialysis or peritoneal dialysis; d) History of nephrotic syndrome.
• • 20. Bleeding risk: a) Coagulation abnormalities: Activated partial hromboplastin time (APTT) or thrombin time (TT) \>1.5×ULN, or international normalized ratio (INR) \>1.5 (\>2.5 for patients requiring anticoagulation therapy); b) History of bleeding (e.g., hemoptysis), coagulation disorders, or current use of warfarin, aspirin, low-molecular-weight heparin, or other antiplatelet agents (except for aspirin ≤100 mg/d for prophylaxis); c) Any signs or history of bleeding diathesis, regardless of severity; d) Active gastrointestinal bleeding, evidenced by hematemesis, hematochezia, or melena within the past 3 months, without resolution confirmed by endoscopy or colonoscopy; e) Any CTCAE ≥ Grade 3 bleeding or hemorrhagic event within 4 weeks before the first dose.
• • 21. Cardiovascular and cerebrovascular abnormalities: a) Any of the following within 12 months before the first dose: ≥ Grade 2 myocardial ischemia, yocardial infarction, arrhythmias, ≥ Grade 3 cardiac insufficiency, uncontrolled angina, coronary/peripheral artery bypass graft surgery, symptomatic congestive heart failure, cerebrovascular accident, or transient ischemic attack; b) Deep vein thrombosis or pulmonary embolism within 6 months before the first dose; c) Left ventricular ejection fraction (LVEF) \<50% assessed by Doppler ultrasound; d) Average QTc interval corrected by Fridericia's formula (QTcF) (based on at least 3 consecutive ECG readings): ≥470 ms for females; e) Uncontrolled hypertension (at least 2 measurements showing systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg).
• • 22. Other factors judged by the investigator as potentially affecting study results or leading to premature termination, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring concurrent treatment, significant laboratory abnormalities, or family/social factors that may compromise patient safety.